Ligand Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St set for higher open as investors weigh fresh US-Iran peace deal reports
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Ligand Pharma (LGND) Tops Q3 EPS by 14c
November 9, 2015 4:03 PM ESTLigand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.56, $0.14 better than the analyst estimate of $0.42. Revenue for the quarter came in at $17.7 million versus the consensus estimate of $17.8 million.
Release of Valuation Allowance
Ligand has accumulated a usable portfolio of net operating loss... More
